Project Grant R01CA286069
Award Date
9/18/24
Completion Date
8/31/29
Dollars Obligated
$595K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Vermont, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $734,785 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Vanderbilt University Medical Center. The 5-year grant, effective September 1, 2024, will fund a proteogenomics study to identify proteins associated with breast cancer risk. The study will integrate genomics and proteomics data from over 5,000 normal breast tissue samples and 125 breast cancer tissue samples to discover putative target proteins for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $653,500.00 to Emory University to develop improved methods for measuring the completeness of cancer registries in the United States. The key products and services to be delivered under this 5-year grant include: Developing advanced statistical methods to estimate cancer registry completeness that account for factors such as cancer type, demographics, geography, and...
This federal Project Grant award, valued at $407,321 and awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), supports research to investigate alternative splicing and isoform expression as mediators of the genetic etiology of breast cancer. The key objectives are to: Quantify isoform expression and alternative splicing events in breast tissue using novel transcript assemblies from long-read RNA sequencing data. This will involve benchmarking statistical...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,935,588 to the University of Washington to conduct research on genomic analysis of inherited breast and ovarian cancer. The key objectives are to: Identify the spectrum of rare non-coding variants in the regulatory regions of known breast cancer genes using long-read genomic sequencing. Characterize the transcriptional consequences of complex structural variants and rare...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at Emory University to characterize the epigenomic and transcriptional features that drive the dynamic regulation of HER2 expression in breast cancer. The $219,491 award, with a project period from March 1, 2025 to February 28, 2027, will enable Emory researchers to: Define exogenous factors and intrinsic features of HER2 that influence its heterogeneity and plasticity in...
The National Cancer Institute (NCI) awarded a $1,285,884 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Houston System to develop clinical decision-support algorithms for designing patient-specific breast molds for tissue shaping in autologous breast reconstruction. The four-year study (August 2024 - July 2028) aims to improve the efficiency of autologous breast reconstruction, an important component of breast cancer rehabilitation,...
This federal Project Grant award of $156,500, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a study titled "Nurses Surviving Breast Cancer: An Exploration of Breast Cancer Diagnosis, Reported Lymphedema Symptoms, and Lifestyle Status in the Nurses' Health Study Survey". The study aims to 1) explore patterns of incidence of self-reported breast cancer-related lymphedema (BCRL) symptoms, and 2) examine...
This $447,340 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Miami aims to identify epigenetic dependencies and vulnerabilities in endocrine-resistant breast cancer. The research focuses on investigating the role of the CoREST-SWI/SNF axis in mediating breast cancer cell plasticity and endocrine therapy resistance, particularly in the context of ESR1 and ARID1A mutations. The project will evaluate the effects of CoREST...
The National Cancer Institute (NCI) awarded a $872,878 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of California, Davis (UC Davis) to conduct the Latin America Genomics of Breast Cancer Risk Study (LAGENO-BCR). The five-year project, which began on September 1, 2024, aims to study the genetic architecture of breast cancer risk in Hispanic/Latina populations and improve predictive models for risk stratification. The project leverages the...
This $434,379 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to characterize the impact of known cancer predisposition mutations and develop models for cancer misdiagnosis using data from the All of Us Research Program. The award will be used by Brigham Young University (BYU) to pursue two key aims: 1) identifying and assessing the intersection of cancer predisposition databases with the All of...